TJ-0113 / PhecdaMed - LARVOL DELTA

Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive Disorder (clinicaltrials.gov) - P2 | N=150 | Not yet recruiting | Sponsor: Hangzhou PhecdaMed Co., Ltd.

New P2 trial • CNS Disorders • Depression • Mood Disorders • Psychiatry

A Clinical Trial of the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing Loss (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Yilai Shu

New trial • Otorhinolaryngology

TJ0113-induced mitophagy in acute liver failure detected by Raman microspectroscopy. (PubMed, Redox Biol) - "Innovations in this test contribute to clinical diagnosis of disease, personalized treatment, effective intraoperative guidance and accurate prognosis. The data may help in the development of a non-invasive clinical device for mitochondrial damage using bedside micro-Raman."

Journal • Hepatology • Inflammation • Liver Failure • Metabolic Disorders • ATG5 • NLRP3

TJ0113 attenuates fibrosis in metabolic dysfunction-associated steatohepatitis by inducing mitophagy. (PubMed, Int Immunopharmacol) - "TJ0113 enhances mitophagy to inhibit lipid accumulation, inflammation and fibrosis formation in MASH, and is a candidate for MASH treatment."

Journal • Fibrosis • Hepatitis B • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • ATG5 • IL1B • IL6 • NLRP3 • TGFB1 • TNFA

Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects (clinicaltrials.gov) - P1 | N=6 | Active, not recruiting | Sponsor: Hangzhou PhecdaMed Co., Ltd. | Not yet recruiting ➔ Active, not recruiting

Enrollment closed

Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects (clinicaltrials.gov) - P1 | N=6 | Not yet recruiting | Sponsor: Hangzhou PhecdaMed Co., Ltd.

New P1 trial

Targeting Mitophagy Enhances Cytotoxicity of Autologously-Derived CAR-T Cells (ASH 2024) - "Tj-CART cells upregulate genes such TCF7, MCL-1, BCL2L1 and so on. Mechanistically, TJ0113 restore CAR-T cell function through recruiting Parkin to damage mitochondrial and inducing mitophagy, thereby leading to mitochondrial metabolic remodeling and potentially driving CAR-T cell stemness decisions via the Wnt/β-catenin pathway.ConclusionsThus, our results reveal that targeting mitophagy is a tangible pathway to optimize autologously-derived CAR-T cells with mitochondrial dysfunction, providing crucial insights into the how mitophagy regulates stemness and orchestrates mitochondrial metabolism."

CAR T-Cell Therapy • IO biomarker • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Metabolic Disorders • Multiple Myeloma • Oncology • BCL2L1 • CCR7 • MCL1 • TCF7

Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease (clinicaltrials.gov) - P2 | N=150 | Not yet recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New P2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease